Thermo Fisher Scientific Inc., the world leader in serving science, announced the opening of a new 8,000-square-meter distribution and labeling center supporting its immunodiagnostics business in Uppsala. The new center strengthens the company’s global supply chain for in vitro diagnostic tests used as an aid in the diagnosis of allergic and autoimmune diseases and is designed to support future growth in demand from healthcare systems worldwide.

Allergic and autoimmune diseases affect as many as two billion people globally, underscoring the need for accurate, reliable and accessible diagnostic solutions. From its immunodiagnostics hub in Uppsala, Thermo Fisher manufactures diagnostic tests that support clinicians in diagnosing and managing these conditions for millions of patients each year.

The distribution and labeling center represents an investment of $18 million (approximately 160 million SEK) in advanced infrastructure, automation and operational capabilities, and complements Thermo Fisher’s* existing research, development and manufacturing activities in Uppsala. It enhances the company’s ability to scale logistics operations, improve efficiency and ensure reliable delivery of high-quality diagnostic products to customers around the world.

The new distribution and labeling center features automated storage, scanning and labeling systems that improve efficiency, accuracy and traceability. Developed in line with Thermo Fisher’s global facility standards, the center incorporates energy-efficient design features.

“The investment in the distribution and labeling center is part of our long-term growth strategy in Sweden and reflects our commitment to meeting future customer demand globally,” said Martin Kjellsson, site leader for Thermo Fisher’s immunodiagnostics business in Uppsala. “By strengthening our logistics capabilities, we are better positioned to scale for future volume while continuing to deliver high-quality products and service to our customers.”

Thermo Fisher’s immunodiagnostics operations in Uppsala develop and manufacture diagnostic solutions used to support the diagnosis and management of asthma, allergy and autoimmune diseases. The business has its roots in scientific research conducted at Uppsala University, where researchers played an instrumental role in the discovery of immunoglobulin E (IgE) more than 50 years ago — a breakthrough that laid the foundation for modern allergy diagnostics. Today, Thermo Fisher’s diagnostics portfolio includes instruments marketed under the Phadia™ brand, as well as ImmunoCAP™ and EliA™ tests.

“Our immunodiagnostics business is focused on enabling patients around the world to receive a timely and accurate diagnosis for allergic and autoimmune diseases,” said Santhosh Nair, president of Thermo Fisher’s immunodiagnostics business. “This investment in Uppsala reflects our continued commitment to innovation, operational excellence and to our Mission to enable our customers to make the world healthier, cleaner and safer.”

Thermo Fisher continues to invest significantly in research and development capabilities globally and in Sweden, building on Uppsala’s strong life science ecosystem and close ties to academia. These investments support the development of new diagnostic technologies and help ensure long-term competitiveness and growth.

Thermo Fisher Scientific has more than 1,500 employees in Sweden across five locations: Uppsala, Stockholm, Gothenburg, Sundbyberg and Ängelholm. Through ongoing investments across diagnostics, life sciences solutions and clinical research, Sweden remains an important hub for Thermo Fisher’s global operations.

*Legal manufacturer: Phadia AB (a part of Thermo Fisher Scientific)